Research
New data supports Hoya's DIMS lenses for myopic prevention among preschool-aged pediatrics
Presented at ARVO, updated findings among the younger pre-myopics confirmed a protective effect of the patented and embedded technology on refractive status.
Research
Hoya reports 8-year data on DIMS spectacle lenses for pediatric myopia
Long-term study evaluated myopia control effect and user experience of patients wearing HOYA’s MiYOSMART spectacle lenses.
Research
DIMS spectacle lenses may mitigate pediatric myopia
Second-ever 6-year clinical trial of myopia control shows no rebound effects after cessation of treatment lens wear.Research
Breakthrough trial finds MiYOSMART iQ spectacle lenses halt childhood myopia progression
Latest 12-month data details highest myopia-control efficacy results reported to date in myopes as young as age 4 wearing HOYA’s D.I.M.S. technology.
Research
HOYA reports 6-month data on MiYOSMART iQ spectacle lenses for pediatric myopia
Interim results find advanced lens and D.I.M.S. triple enhanced design tech to be twice as effective in controlling axial elongation and disease progression.
Products
Hoya Vision launches spectacle lenses for pediatric myopia protection
The MiYOSMART photochromic and polarized spectacle lenses incorporate D.I.M.S. technology.
Research
PRK linked to more postop dry eye, visual disturbances than LASIK
Registry data shows that complication risk shifts by procedure and recovery window, with PRK carrying higher early rates of dry eye and visual disturbances.
Pipeline
Opus Genetics releases positive phase 1/2 data in BEST1 retinal disease
Promising early results pave the way for a higher-dose cohort; FDA meeting signals potential phase 3 trial in 2027.
Business
AMA supports formal classification of myopia as a disease
Adopted resolution calls for comprehensive insurance coverage and reimbursement for evidence-based treatments demonstrated to slow myopia progression.
Research
Researchers identify higher post-cataract TED risk in patients with thyroid disease
Patients demonstrate up to 51% higher risk of developing TED in the year after surgery, with hyperthyroid patients facing more than double the risk.
Products
Orasis adds free first fill, in-office dispensing for QLOSI
Two new access routes let ECPs start patients on prescription-based presbyopia drop, without routing through a direct-to-patient pathway.
Research
Real-world data finds anti-VEGF use may not disrupt IZERVAY dosing patterns
IRIS Registry study demonstrates similarities in safety and dosing intervals among patients undergoing concomitant anti-VEGF and IZERVAY therapy.
Research
Aquatic virus linked to new human eye disease
Covert mortality nodavirus, a pathogen of farmed shrimp and fish, presented in the eye tissue of patients with a vision-threatening uveitis emerging in China.
Business
NeuroVision expands retinal imaging-based neurodegenerative disease detection with new acquisition
Retinal imaging developer adds Durin Life Sciences’ noninvasive, blood-based biomarker test to its integrated platform targeting cognitive diseases.
Research
Real-world TED data finds disease advances beyond acute phase
Real-world study demonstrates heterogeneous disease progression in TED, challenging the traditional self-limited paradigm.
Products
Marco Lombart named exclusive US distributor for Haag-Streit diagnostic technology
Agreement extends to the Lenstar 900 optical biometer and Octopus 600 and 900 perimeter devices.
Research
Could human breast milk treat dry eye disease?
Narrative review traces ophthalmic uses of human milk back to anciant Egyptian papyrus, finding the biology behind it might hold up.
Research
Dry eye may indicate early signs of autoimmune disease
Study findings suggest ocular surface symptoms may precede systemic autoimmune diagnosis by several years.
Research
Study: CV risk score identifies future eye disease risk
Pooled Cohort Equations (PCE) score may help identify high-risk patients when preventive measures may protect their vision.
Research